Ryanodine receptor inhibitors and methods relating thereto
申请人:Chen Wayne S.R.
公开号:US20070254849A1
公开(公告)日:2007-11-01
The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca
2+
release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca
2+
-induced Ca
2+
release (CICR), thereby providing beneficial effects in cardiac therapy.
STORE OVERLOAD-INDUCED CALCIUM RELEASE INHIBITORS AND METHODS FOR PRODUCING AND USING THE SAME
申请人:BACK Tom
公开号:US20160214973A1
公开(公告)日:2016-07-28
The present invention provides compounds having store overload-induced Ca
2+
release (SOICR) inhibitory activity and methods for producing and using the same. In particular, compounds of the invention is of the formula: R
1
—X
1
-L-X
2
—R
2
, wherein R
1
, X
1
, L, X
2
, and R
2
are those defined herein.